CDXS
Codexis Inc.

2,231
Mkt Cap
$152.55M
Volume
4.98M
52W High
$6.08
52W Low
$1.61
PE Ratio
-2.06
CDXS Fundamentals
Price
$1.69
Prev Close
$2.04
Open
$1.64
50D MA
$2.48
Beta
2.12
Avg. Volume
597,052.04
EPS (Annual)
-$0.8892
P/B
2.74
Rev/Employee
$315,664.89
Loading...
Loading...
News
all
press releases
Codexis (NASDAQ:CDXS) Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS
Codexis (NASDAQ:CDXS - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of -46.67% and -53.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.39% and -85.07%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +14.29% and +2.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis Manufacturing Platform for Therapeutic siRNA Manufacturing
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis Manufacturing Platform for Therapeutic siRNA Manufacturing Codexis and Nitto Denko Avecia Enter Evaluation...
PR Newswire·11d ago
News Placeholder
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +5.88% and +2.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -14.46% and -66.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates
Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates
Regeneron (REGN) delivered earnings and revenue surprises of +60.52% and +9.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago

Latest CDXS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.